AstraZeneca Reports Strong Q1 2026 Results; Stock Sees Unusual Options Activity

AstraZeneca reported a "strong Q1" for 2026, with total revenue increasing 8% and operating profit rising 12%, as demand for newer medicines and continued pipeline progress drove growth. The company also saw unusual options trading activity, with 167,020 call options bought on a single day, an increase of approximately 3,235% compared to the typical daily volume of 5,008 call options.

Core EPS rose 5% to $2.58, product revenue rose 8%, and alliance revenue increased 26%. Core gross margin was 83%, and the company expects a stable to slightly higher core gross margin for the full year versus 2025. Core R&D expenses increased 8%, with active clinical trials up 10% and patient enrollment up 30% year-over-year. Operating cash flow was $3.4 billion, down slightly versus the prior year due to a large milestone receipt in Q1 2025, and capital expenditure reached $600 million. Net debt rose by about $2.5 billion during the quarter. The company reiterated full-year guidance: total revenue is expected to increase by a mid-to-high single-digit percentage, and core EPS is expected to increase by a low double-digit percentage at constant exchange rates.

Oncology revenue increased 16% to $6.8 billion, with double-digit growth in all regions. Tagrisso revenue grew 5% to $1.8 billion. Imfinzi and Imjudo grew 28% in aggregate, with Imfinzi up 30%. Calquence grew 17% to more than $900 million. Enhertu grew 34% and is "annualizing as a $5 billion brand." Truqap revenue was $198 million, up 47%, and Datroway revenue was $43 million. The company expects a potential U.S. approval of TROPION-Breast02 later in the quarter.

In pipeline news, phase III EMERALD-3 results in hepatocellular carcinoma showed a statistically significant and clinically meaningful improvement in progression-free survival for the Imfinzi plus Imjudo (STRIDE) plus lenvatinib arm with transarterial chemoembolization, with a positive trend to overall survival. The STRIDE-only arm showed a strong trend to PFS and OS but was not formally tested. Data will be presented at ASCO.

AstraZeneca stock traded down $0.18 to $208.49 on Thursday, with volume of 1,951,933 shares compared to an average volume of 4,001,978. The company has a market cap of $323.35 billion, a P/E ratio of 69.27, and a beta of 0.34. Its 52-week range is $122.48 to $212.71. Institutional investors and hedge funds own 20.35% of the company's stock.

The company also disclosed a dividend of $1.595 per share, payable on March 23rd to shareholders of record on February 20th, with an ex-dividend date of February 20th. The dividend payout ratio is 74.83%.

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England, formed through the 1999 merger of Astra AB and Zeneca Group. It generates about $60.4 billion in revenue, almost entirely from its pharmaceuticals business, and focuses on oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. Its portfolio includes Tagrisso, Imfinzi, Farxiga, and Enhertu. The company has a late-stage pipeline with multiple cancer and cardiovascular assets progressing through regulators and new AI partnerships aimed at making drug development more efficient. It faces risks including dependence on a handful of blockbuster drugs, ongoing R&D spend, and pricing and biosimilar pressure on products such as Soliris and Farxiga.